Page 4 - Commodore Capital News Today

Commodore Capital LP reduced its stake in shares of Ambrx Biopharma Inc. (NYSE:AMAM – Free Report) by 33.9% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,175,000 shares of the company’s stock after selling 1,628,447 shares during the quarter. Ambrx Biopharma comprises about […]

Commodore Capital LP lifted its holdings in Cogent Biosciences, Inc. (NASDAQ:COGT – Free Report) by 16.6% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 5,566,026 shares of the technology company’s stock after acquiring an additional 793,605 shares during the period. […]

/PRNewswire/ -- Spyre Therapeutics, Inc. ("Spyre") (NASDAQ: SYRE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to...

Shares of Cabaletta Bio, Inc. (NASDAQ:CABA – Get Free Report) traded down 4.2% during trading on Monday . The company traded as low as $17.17 and last traded at $17.20. 167,698 shares changed hands during trading, a decline of 70% from the average session volume of 560,050 shares. The stock had previously closed at $17.96. […]

Fasedienol (PH94B) PALISADE Phase 3 Program for acute treatment of social anxiety disorder (SAD) advancing to build on recent positive PALISADE-2 Phase 3 results Preparations to initiate potential fasedienol

– Stephen Mahoney appointed President and Chief Executive Officer – – Potential best-in-class subcutaneous and intravenous thyroid eye disease programs targeting insulin-like growth factor 1...

Akero Therapeutics, Inc. (NASDAQ:AKRO – Get Free Report) hit a new 52-week low during mid-day trading on Friday after UBS Group lowered their price target on the stock from $83.00 to $39.00. UBS Group currently has a buy rating on the stock. Akero Therapeutics traded as low as $14.03 and last traded at $14.05, with […]

SAB also announces closing of $7.5 million financing, the first tranche of $130 million private placementSIOUX FALLS, S.D., Oct. 05, 2023 -- SAB Biotherapeutics ; class=js-l-obf link...

Vistagen Therapeutics, Inc. , a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous...

SAB Biotherapeutics (NASDAQ: SABS) has entered into a securities purchase agreement with certain investors to issue and sell shares of preferred stock in a private placement of up to $130 million in gross proceeds.